SCHEMBL3427795

SCHEMBL3427795

c1cc(NC2CCCCC2)cc(NC2CCCCC2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
MAPT P10636 3/20 0.49
HSD17B10 Q99714 2/20 0.49
APAF1 O14727 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPK1 P28482 1/20 0.49
BLM P54132 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
GAA P10253 4/20 0.47
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.44
IP6K1 Q92551 1/20 0.44
RAB9A P51151 5/20 0.44
NPC1 O15118 4/20 0.44
EPHX1 P07099 2/20 0.44
EPHX2 P34913 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3768702 0.98 KDM4E (0.46) KDM4EMEN1KMT2AMAPTHSD17B10
SCHEMBL7050567 0.89 MAPT (0.57) KDM4EMEN1KMT2AMAPTHSD17B10
SCHEMBL21799663 0.88 KDM4E (0.50) KDM4EMEN1KMT2AMAPTHSD17B10
SCHEMBL29922322 0.88 KDM4E (0.50) KDM4EMEN1KMT2AMAPTHSD17B10
SCHEMBL10346361 0.86 CYP3A4 (0.46) KDM4EMEN1KMT2AMAPTHSD17B10
SCHEMBL3499884 0.86 TDP1 (0.48) KDM4EMEN1KMT2AMAPTHSD17B10
SCHEMBL10346526 0.86 CYP3A4 (0.46) KDM4EMEN1KMT2AMAPTHSD17B10
SCHEMBL8090787 0.86 CYP3A4 (0.46) KDM4EMEN1KMT2AMAPTHSD17B10
SCHEMBL31195429 0.86 CYP3A4 (0.46) KDM4EMEN1KMT2AMAPTHSD17B10
SCHEMBL3477718 0.86 EPHX2 (0.60) MEN1KMT2AMAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156441-A1 Cycloalkyl phenylenediamines as deposit control agents for lubricants GREAT LAKES CHEMICAL GLOBAL, INC. 2009-06-18 US claimed
CN-115260041-A Novel anti-aging agent and preparation method thereof 王兴路 2022-11-01 CN disclosed
EP-2245123-B1 METHODS FOR PRODUCING ALKYLATED 1,3 BENZENEDIAMINE COMPOUNDS CHEMTURA CORP (US) 2017-07-19 EP disclosed
US-8563489-B2 Alkylated 1,3-benzenediamine compounds and methods for producing same CHEMTURA CORPORATION (US) 2013-10-22 US disclosed
EP-2245123-A2 ALKYLATED 1,3 BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME Chemtura Corporation (US) 2010-11-03 EP disclosed
WO-2009076091-A2 ALKYLATED 1,3 BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME CHEMTURA CORPORATION (US) 2009-06-18 WO disclosed
US-20090156441-A1 Cycloalkyl phenylenediamines as deposit control agents for lubricants GREAT LAKES CHEMICAL GLOBAL, INC. 2009-06-18 US disclosed
US-20090156449-A1 ALKYLATED 1,3-BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME LANXESS SOLUTIONS US INC. 2009-06-18 US disclosed
US-20040156933-A1 Polymer additives with improved permanence and surface affinity CIBA SPECIALTY CHEMICALS CORP. 2004-08-12 US disclosed
US-5710335-A REACTING RESORCIN WITH PRIMARY AMINE THEN ALKYL HALIDE MITSUI TOATSU CHEMICALS, INC. (JP) 1998-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156449-A1 ALKYLATED 1,3-BENZENEDIAMINE COMPOUNDS AND METHODS FOR PRODUCING SAME BBOX1, ABHD5, BRD1 KDM4E 2055/4885MEN1 4468/4885KMT2A 2281/4885
US-20090156441-A1 Cycloalkyl phenylenediamines as deposit control agents for lubricants C5, C9, C1S KDM4E 4043/4885MEN1 3617/4885KMT2A 3857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.